Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alastair J King

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
ACS Pharmacology & Translational Science|February 19, 2026
Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures"Antonia C Darragh, Andrew M Hanna, Justin Lipner, et al.
International Journal of Molecular Sciences|September 14, 2024
Impact of Methylated Cyclodextrin KLEPTOSE<sup>®</sup> CRYSMEB on Inflammatory Responses in Human In Vitro ModelsDamien Truffin, Flora Marchand, Mathias Chatelais, et al.
Analytical and Bioanalytical Chemistry|November 7, 2007
A cell-based screening method for specifically detecting kinase activityMikiya Suda, Tsuyoshi Ishii, Hiroshi Sootome, et al.
ACS Pharmacology & Translational Science|April 17, 2025
Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic SignaturesAntonia C Darragh, Andrew M Hanna, Justin H Lipner, et al.
Journal of Biomolecular Screening|May 23, 2007
A robust, target-driven, cell-based assay for checkpoint kinase 1 inhibitorsTsuyoshi Ish, Hiroshi Sootome, Alastair J King, et al.
ACS Pharmacology & Translational Science|May 14, 2026
Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures"Antonia C Darragh, Andrew M Hanna, Justin H Lipner, et al.
Gastroenterology|April 29, 2008
The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesisKazuhiro Noma, Keiran S M Smalley, Mercedes Lioni, et al.
Cancer Research|July 18, 2008
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpressionKeiran S M Smalley, Rooha Contractor, Thiennga K Nguyen, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2006
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analoguesLata T Gooljarsingh, Christine Fernandes, Kang Yan, et al.
Molecular Cancer Therapeutics|September 16, 2008
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomasKeiran S M Smalley, Mercedes Lioni, Maurizia Dalla Palma, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
ACS Pharmacology & Translational Science|February 19, 2026
Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures"Antonia C Darragh, Andrew M Hanna, Justin Lipner, et al.
International Journal of Molecular Sciences|September 14, 2024
Impact of Methylated Cyclodextrin KLEPTOSE<sup>®</sup> CRYSMEB on Inflammatory Responses in Human In Vitro ModelsDamien Truffin, Flora Marchand, Mathias Chatelais, et al.
Analytical and Bioanalytical Chemistry|November 7, 2007
A cell-based screening method for specifically detecting kinase activityMikiya Suda, Tsuyoshi Ishii, Hiroshi Sootome, et al.
ACS Pharmacology & Translational Science|April 17, 2025
Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic SignaturesAntonia C Darragh, Andrew M Hanna, Justin H Lipner, et al.
Journal of Biomolecular Screening|May 23, 2007
A robust, target-driven, cell-based assay for checkpoint kinase 1 inhibitorsTsuyoshi Ish, Hiroshi Sootome, Alastair J King, et al.
ACS Pharmacology & Translational Science|May 14, 2026
Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures"Antonia C Darragh, Andrew M Hanna, Justin H Lipner, et al.
Gastroenterology|April 29, 2008
The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesisKazuhiro Noma, Keiran S M Smalley, Mercedes Lioni, et al.
Cancer Research|July 18, 2008
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpressionKeiran S M Smalley, Rooha Contractor, Thiennga K Nguyen, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2006
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analoguesLata T Gooljarsingh, Christine Fernandes, Kang Yan, et al.
Molecular Cancer Therapeutics|September 16, 2008
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomasKeiran S M Smalley, Mercedes Lioni, Maurizia Dalla Palma, et al.
Pageof 2